Unfortunately we don’t yet know yet if m6A is important for cancer patients. Yes we have a huge amount of scientific data that suggests m6A is important, but until we have cancer patients respond to m6A drugs we won’t know for sure.
I should add that based on what I know I would be very, very surprised if m6A is not important in cancer and a whole range of other diseases. I would also add that I think increasing m6A levels is going to be more important than decreasing it for cancer - i.e. inhibit FTO, not METTL3.
Industry news, page-1681
-
- There are more pages in this discussion • 138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
-0.105(5.74%) |
Mkt cap ! $293.8M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.82 | $1.70 | $240.3K | 138.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 270 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |